PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 38 filers reported holding PROTAGONIST THERAPEUTICS INC in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $658,000 | -2.8% | 76,640 | +135.6% | 0.00% | – |
| Q4 2017 | $677,000 | +63.1% | 32,534 | +38.4% | 0.00% | – |
| Q3 2017 | $415,000 | +57.2% | 23,508 | +0.6% | 0.00% | – |
| Q2 2017 | $264,000 | +5.2% | 23,372 | +19.5% | 0.00% | – |
| Q1 2017 | $251,000 | -50.2% | 19,560 | -14.7% | 0.00% | – |
| Q4 2016 | $504,000 | +136.6% | 22,918 | +127.1% | 0.00% | – |
| Q3 2016 | $213,000 | – | 10,093 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $84,864,191 | 21.18% |
| Cannon Global Investment Management, LLC | 69,900 | $2,422,035 | 11.28% |
| ADAR1 Capital Management, LLC | 1,603,932 | $55,576,244 | 10.49% |
| Checkpoint Capital L.P. | 355,000 | $12,300,750 | 7.42% |
| Fairmount Funds Management LLC | 931,890 | $32,289,989 | 3.65% |
| BVF INC/IL | 3,319,290 | $115,013,399 | 3.22% |
| RTW INVESTMENTS, LP | 5,286,404 | $183,173,899 | 2.84% |
| Kynam Capital Management, LP | 800,000 | $27,720,000 | 2.14% |
| 683 Capital Management, LLC | 604,449 | $20,944,158 | 1.58% |
| Birchview Capital, LP | 48,000 | $1,663,200 | 1.54% |